Table 2.
Studies on cell-free fetal DNA (cffDNA) in prediction of pre-eclampsia.
| Study | Marker to quantify cffDNA | Gestational age (in weeks) | Results in prediction of pre-eclampsia |
|---|---|---|---|
| Salvianti et al. (2015) | Hypermethylated RASSF1A | 8–17 | Cutoff value of 7.49 GE/ml in cffDNA concentration with 100% sensitivity and 50% specificity |
| Papantoniou et al. (2013) | Hypermethylated RASSF1A | 11–13 | Cutoff value of 512 GE/ml in cffDNA values with specificity and sensitivity of 100% |
| Poon et al. (2013) | Chromosome selective sequencing of single nucleotide polymorphic and nonpolymorphic loci | 11–13 | No significant difference in values between pre-eclampsia cases and normal |
| Yu et al. (2013) | SRY | 15–20 (18) | Cutoff value (logged) of 2.62 with a sensitivity of 90% and specificity of 85% for early-onset pre-eclampsia |
| Kim et al. (2012) | Hypermethylated RASSF1A | 15–28 | 3.3-fold increase in cffDNA concentration |
| Sifakis et al. (2009) | DYS | 11–13 | Significant increase in cffDNA only in early-onset pre-eclampsia (95.5 vs 51.5 GE/ml) and not in late-onset group |
| Gozdziewicz et al. (2009) | SRY | 15–22 (18) | Significant increase in cffDNA values (3.2 vs 0.595 GE/ml) |
| Crowley et al. (2007) | SRY | 10–20 (13.5) | No significant increase in cffDNA before 20 weeks (30.5 vs 27.5 GE/ml) |
| Cotter et al. (2005) | RhD | 9–22 (15.3) | Fourfold increase risk of disease development for tenfold increase of copies/ml |
| Levine et al. (2004) | DYS | 17–28 | Increase but not significant in 17–24 weeks and significant rise from 24 to 28 weeks |
| Cotter et al. (2004) | SRY | 15.7 ± 3.6 | Increase in cffDNA is associated with 8-fold risk of disease development |
| Farina et al. (2004) | DYS | 20 ± 2.08 | 2.39-fold increase of cffDNA in low-risk population |
| Zhong et al. (2002) | SRY | 19–24 (21.0) | Significant increase with 422.9 vs 128.5 copies/ml |
| Leung et al. (2001) | SRY | 11–22 (17) | Significant increase with 41.9 vs 22.0 GE/ml |